Sourcebio International PLC
LSE:SBI

Watchlist Manager
Sourcebio International PLC Logo
Sourcebio International PLC
LSE:SBI
Watchlist
Price: 115 GBX 4.55%
Market Cap: £78.4m

Sourcebio International PLC
Investor Relations

SourceBio International Plc engages in the provision of laboratory services in healthcare, clinical, life science research, and biopharma industries. The company is headquartered in Nottingham, Nottinghamshire. The company went IPO on 2020-10-29. The firm operates through four business segments: Infectious Disease Testing, Healthcare Diagnostics, Genomics and Stability Storage. Its Infectious Disease Testing segment offers COVID-19 antigen reverse transcription-polymerase chain reaction (RT-PCR) testing services to the national health service (NHS), private healthcare providers and private industry. Its Healthcare Diagnostics segment offers histopathology and clinical diagnostic services for the NHS and private healthcare across the United Kingdom and Ireland. Its Genomics segment offers deoxyribonucleic acid (DNA) sequencing services for pharmaceutical and biotechnology companies, academia, contract research organizations (CROs) and other research groups in the United Kingdom, Europe and North America. Its Stability Storage segment offers shelf-life testing services and equipment for pharmaceutical companies and others.

Show more
Loading
SBI
FTSE All Share Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Jay Charles LeCoque
Exec. Chairman
No Bio Available
Mr. Anthony James Ratcliffe ACA, BSc, MBA
CFO, Company Sec. & Exec. Director
No Bio Available
Mr. Russell Wheatcroft
Chief Operating Officer
No Bio Available

Contacts

Address
NOTTINGHAMSHIRE
Nottingham
1 Orchard Place, Nottingham Business Park
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett